Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. 00512
00512 logo

00512 Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
7.440
Open
7.180
VWAP
7.37
Vol
6.27M
Mkt Cap
--
Low
7.180
Amount
46.20M
EV/EBITDA(TTM)
11.23
Total Shares
--
EV
28.80B
EV/OCF(TTM)
18.25
P/S(TTM)
2.15

Events Timeline

No data

No data

News

aastocks
7.5
2025-12-23aastocks
GRAND PHARMA Obtains Exclusive Rights to Market Allergy Medication Neffy in China
  • Product Cooperation Agreement: GRAND PHARMA has entered into a product cooperation agreement with Pediatrix Therapeutics for the adrenaline nasal spray, Neffy.

  • Commercialization Rights: The Group will acquire exclusive commercialization rights in Mainland China and non-exclusive rights in Hong Kong for Neffy.

  • Localized Production Plans: GRAND PHARMA plans to achieve localized production of Neffy within 24 months after receiving product approval.

  • Short Selling Information: The company has reported short selling of $3.75 million with a ratio of 26.016%.

aastocks
9.0
2025-08-13aastocks
<Research>CICC Expects Commercial Insurance Innovative Drug Catalog Adjustments to Help High-Value Innovative Drugs Land
  • Drug Catalog Adjustments: China's NHSA has announced the preliminary review of adjustments to drug catalogs for basic medical insurance, maternity insurance, work injury insurance, and commercial insurance, with 534 drugs passing the review. A dual catalog mechanism is expected to be implemented to differentiate between essential clinical drugs and high-value innovative drugs.

  • Investment Opportunities: CICC predicts that the expansion of commercial insurance will encourage investment in innovative drug R&D, benefiting companies like BEIGENE and others listed, as they focus on high-value drugs not covered by standard medical insurance.

aastocks
4.0
2025-08-13aastocks
<Research>CICC Ratings, TPs on Medical Health Stocks (Table)
  • Stock Performance Overview: Several pharmaceutical stocks in Hong Kong, including SKB BIO-B and INNOVENT BIO, showed positive gains with notable short selling ratios, indicating varying investor sentiments and market dynamics.

  • Market Insights: Analysts maintain an "Outperform" rating on multiple companies like HENGRUI PHARMA and CSPC PHARMA, highlighting strong fundamentals despite some stocks experiencing price weakness.

Wall Street analysts forecast 00512 stock price to rise
0 Analyst Rating
Wall Street analysts forecast 00512 stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for (00512.HK) is 12.79, compared to its 5-year average forward P/E of 9.00. For a more detailed relative valuation and DCF analysis to assess 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
9.00
Current PE
12.79
Overvalued PE
11.70
Undervalued PE
6.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
5.82
Current EV/EBITDA
9.13
Overvalued EV/EBITDA
8.75
Undervalued EV/EBITDA
2.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.74
Current PS
2.17
Overvalued PS
2.29
Undervalued PS
1.19

Financials

AI Analysis
Annual
Quarterly

Whales Holding 00512

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is (00512) stock price today?

The current price of 00512 is 7.38 USD — it has increased 2.79

What is (00512)'s business?

What is the price predicton of 00512 Stock?

Wall Street analysts forecast 00512 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 00512 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is (00512)'s revenue for the last quarter?

revenue for the last quarter amounts to NaN USD, decreased

What is (00512)'s earnings per share (EPS) for the last quarter?

. EPS for the last quarter amounts to USD, decreased

How many employees does (00512). have?

(00512) has 0 emplpoyees as of March 10 2026.

What is (00512) market cap?

Today 00512 has the market capitalization of 0.00 USD.